Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Pretomanid Formulations in Healthy Adults
NCT04309656Phase 1Completed
- Sponsor
- TB Alliance
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pretomanid in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by TB Alliance. Primary endpoints: Maximum Plasma Concentration at 96 hours, Area Under the Curve from time 0 to last measurable concentration at 96 hours and 1 more. Started Jan 2020; status: completed.
02
Drugs
pretomanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT04309656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309656.